Skip to content
Stock screener

CANF Can-Fite BioPharma Ltd. stock chart & analysis

Conviction 45Scan · Wed, Nov 18, 2026

Can-Fite BioPharma Ltd. (CANF) closed at $1.48 (-3.27%) on Nov 18, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 34, RS Rating 5, -88.0% from its 52-week high, -63.0% year to date.

CANF$1.48-3.27%
ResistanceSupportVol 14
Loading chart…

Why CANF moved

From the StockSetups movers recaps that covered CANF, newest first. A recap states what was known that day.

Can-Fite BioPharma Ltd.www.canfite.com ↗
Price1.48
Change-3.27%
Gap-1.31%
Rel volume0.32×
Avg volume74.91K
Avg $ vol125.19K
SMA 201.62
SMA 501.91
SMA 2003.04
Price vs 50-22.52%
Price vs 200-51.31%
MA stackbearish
50/200 cross—
Supertrenddown · 1.77
RSI (14)34
MACD hist0.01
MACD cross—
Stoch %K / %D21 / 37
ADX (14)69
+DI / −DI6 / 28
RSI divergence—
MACD divergence—
ATR %6.70%
ADR %5.68%
52w high12.30
52w low1.42
From 52w high-87.97%
Above 52w low+4.23%
New 52w highNo
SqueezeOff
Bollinger width23.69%
%B0.13
Donchian pos12.24%
Donchian high1.91
Donchian low1.42
AVWAP (52w high)4.89
vs AVWAP high-69.72%
AVWAP (52w low)1.51
vs AVWAP low-1.91%
OBV trendDown
Chaikin MF (20)0.08
Today vs 20d0.32×
Avg vol (14d)34.01K
Avg vol (20d)74.91K
Avg $ vol (20d)125.19K
Market cap—
RS Rating5 / 99
RS 3m (vs SPY)-51.59%
RS 6m (vs SPY)-55.75%
RS line new highNo
Trend template0/8
Technical rank17.0
1 week-4.52%
1 month-21.69%
3 months-55.82%
6 months-57.23%
1 year-79.56%
YTD-63.00%
P/E—
P/B0.73
P/S—
P/FCF—
EPS—
Div yield—
ROE—
ROA—
Debt/Eq—
Current3.46
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth—
Price target—
Target upside—
Analyst rating—
Institutional1.92%
Ent. value-1.47M
Revenue—
Net income—
Gross profit—
Free cash flow—
Industry—
ExchangeNYSE
Shares out—
Employees5
ListedMon, Sep 10, 2012
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction45 / 100
Pattern quality—
Tech rank17.0 / 100
Group rank—
Status laneNo active setup
Setup direction—
Pattern family
Resistance2.10
Support1.46
Days since event—
Candle confirm—

CANF technical analysis

Trend

CANF is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 22.5% below the 50-day ($1.91) and 51.3% below the 200-day ($3.04). ADX(14) at 69 points to a strong, established trend. It meets 0 of 8 trend-template criteria.

Momentum

RSI(14) is 34, in the bearish half of its range. The MACD histogram is positive. Its RS Rating of 5 puts its weighted 12-month performance ahead of about 5% of the US market.

Volume and volatility

Volume on the latest session ran 0.3× its 20-day average. It trades about $125,189 a day on average. ATR(14) is $0.0991, 6.7% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (0.08) shows accumulation.

Key levels

The chart pattern's support is $1.46 and its resistance $2.10. The 52-week range is $1.42 to $12.30; price is 88.0% below the high and 4.2% above the low. The VWAP anchored at the 52-week high is $4.89, above price.

Performance

CANF returned -4.5% (1 week), -21.7% (1 month), -55.8% (3 months), -57.2% (6 months), -79.6% (1 year), -63.0% (year to date).

About Can-Fite BioPharma Ltd.

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

Listed 2012 · 5 employees

Insider activity

SEC Form 4 transactions in CANF

InsiderSideShares
Farbstein Motti
CEO, CFO and COO · Options to Purchase Ordinary Shares · 2026-06-04
Grant24K
Fishman Pnina
Chief Scientific Officer · Options to Purchase Ordinary Shares · 2026-06-04
Grant24K

SEC filings

EDGAR filings in CANF · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.

Start free — 7-day trial, no card →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.